ABIONYX Pharma S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABNX.PA research report →
About the company
ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. This compound is designed to mimic the structural and functional attributes of pre-beta HDL, utilizing human recombinant apoA-I (a natural high-density lipoprotein protein) along with natural phospholipids like sphingomyelin and dipalmitoylphosphatidylglycerol.
- CEO
- Sir Cyrille Tupin
- IPO
- 2015
- Employees
- 51
- HQ
- Balma, FR
Price Chart
- Market Cap
- $75.35M
- P/E
- -13.60
- P/S
- 18.54
- P/B
- 18.15
- EV/EBITDA
- -13.26
- Div Yield
- 0.00%
- Gross Margin
- 10.26%
- Op Margin
- -153.91%
- Net Margin
- -136.42%
- ROE
- -114.60%
- ROIC
- -65.53%
- Revenue
- $4.06M · -11.67%
- Net Income
- $-5,550,000 · -26.14%
- EPS
- $-0.16 · -23.08%
- Op Income
- $-6,255,000
- FCF YoY
- 11.81%
- 52W High
- $5.29
- 52W Low
- $1.17
- 50D MA
- $3.21
- 200D MA
- $3.57
- Beta
- 0.49
- Avg Volume
- 162.74K
Get TickerSpark's AI analysis on ABNX.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ABNX.PA coverage
Recent articles, reports, and earnings notes.
No research on ABNX.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ABNX.PA report →Similar companies
Peers in the same neighborhood.